The US Food and Drug Administration (FDA) has granted approval to acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).  The regulator also granted approval to acalabrutinib as a single agent for adults with previously treated MCL.  The decision […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!